Does Rallies show Form 4 insider transactions for TARS?

Yes. Rallies tracks TARS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is TARS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TARS. It does not provide personalized investment advice.

TARS (Tarsus Pharmaceuticals, Inc. Common Stock) Stock Analysis - Insider Trades

Tarsus Pharmaceuticals, Inc. Common Stock (TARS) is a publicly traded Healthcare sector company. As of May 21, 2026, TARS trades at $64.83 with a market cap of $2.70B and a P/E ratio of -56.22. TARS moved +5.71% today. Year to date, TARS is -18.76%; over the trailing twelve months it is +44.36%. Its 52-week range spans $31.36 to $85.25. Analyst consensus is strong buy with an average price target of $95.17. Rallies surfaces TARS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading TARS stock inside the company?

Recent TARS insider activity includes Neervannan Seshadri sold 2.99K, Whitfield Dianne C. sold 4.17K, Wahl Bryan sold 4.23K, Neervannan Seshadri sold 4.59K, and Mottiwala Aziz sold 4.44K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

TARS Key Metrics

Key financial metrics for TARS
Metric	Value
Price	$64.83
Market Cap	$2.70B
P/E Ratio	-56.22
EPS	$-1.13
Dividend Yield	0.00%
52-Week High	$85.25
52-Week Low	$31.36
Volume	15
Avg Volume	0
Revenue (TTM)	$535.08M
Net Income	$-48.27M
Gross Margin	0.00%

Recent TARS Insider Trades

Neervannan Seshadri sold 2.99K (~$199.52K) on Mar 20, 2026.
Whitfield Dianne C. sold 4.17K (~$279.66K) on Mar 19, 2026.
Wahl Bryan sold 4.23K (~$283.48K) on Mar 19, 2026.
Neervannan Seshadri sold 4.59K (~$307.46K) on Mar 19, 2026.
Mottiwala Aziz sold 4.44K (~$297.48K) on Mar 19, 2026.

Latest TARS News

Tarsus Doses First Participant in 700-Subject Phase 2 Lyme Prevention Trial — Mar 31, 2026
Tarsus Q4 Revenue $151.7M Beats Estimates; Price Targets Raised to $105, $90 — Mar 6, 2026
Tarsus Pharmaceuticals Posts 150% Revenue Surge to $451M, Eyes $2B Peak Xdemvy Sales — Feb 24, 2026
Tarsus Pharmaceuticals’ Q4 revenue rises 128% but EPS misses slightly — Feb 24, 2026
Tarsus Reports 150% Sales Growth to $451.4M, Launches Phase 2 Programs — Feb 23, 2026

TARS Analyst Consensus

8 analysts cover TARS: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $95.17.

Common questions about TARS

Who is trading TARS stock inside the company?: Recent TARS insider activity includes Neervannan Seshadri sold 2.99K, Whitfield Dianne C. sold 4.17K, Wahl Bryan sold 4.23K, Neervannan Seshadri sold 4.59K, and Mottiwala Aziz sold 4.44K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for TARS?: Yes. Rallies tracks TARS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is TARS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TARS. It does not provide personalized investment advice.